Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing by Sandling, Johanna K. et al.
  109Sandling JK, et al. Ann Rheum Dis 2021;80:109–117. doi:10.1136/annrheumdis-2020-218636
Systemic lupus erythematosus
TRANSLATIONAL SCIENCE
Molecular pathways in patients with systemic lupus 
erythematosus revealed by gene- centred 
DNA sequencing
Johanna K Sandling   ,1 Pascal Pucholt   ,1 Lina Hultin Rosenberg,2 
Fabiana H G Farias,2,3 Sergey V Kozyrev,2 Maija- Leena Eloranta,1 Andrei Alexsson,1 
Matteo Bianchi,2 Leonid Padyukov,4 Christine Bengtsson,5 Roland Jonsson,6 
Roald Omdal,6,7 Benedicte A Lie,8 Laura Massarenti,9 Rudi Steffensen,10 
Marianne A Jakobsen,11 Søren T Lillevang,11 on behalf of the ImmunoArray 
Development Consortium and DISSECT consortium, Karoline Lerang,12 
Øyvind Molberg,12,13 Anne Voss,14 Anne Troldborg,15,16 Søren Jacobsen,17,18 
Ann- Christine Syvänen,19 Andreas Jönsen,20 Iva Gunnarsson,4 
Elisabet Svenungsson   ,4 Solbritt Rantapää-Dahlqvist,5 Anders A Bengtsson,20 
Christopher Sjöwall   ,21 Dag Leonard,1 Kerstin Lindblad- Toh,2,22 Lars Rönnblom   1
To cite: Sandling JK, 
Pucholt P, Hultin Rosenberg L, 
et al. Ann Rheum Dis 
2021;80:109–117.
Handling editor Josef S 
Smolen
 ► Additional material is 
published online only. To view, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
annrheumdis- 2020- 218636).
For numbered affiliations see 
end of article.
Correspondence to
Dr Johanna K Sandling and 
Professor Lars Rönnblom, 
Department of Medical Sciences, 
Rheumatology, Rudbeck 
laboratory C11, Uppsala 
University, Uppsala 75185, 
Sweden;  
 johanna. sandling@ medsci. uu. 
se,  
 Lars. Ronnblom@ medsci. uu. se
Received 20 July 2020
Revised 15 September 2020
Accepted 16 September 2020
Published Online First 
9 October 2020
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
Objectives Systemic lupus erythematosus (SLE) is an 
autoimmune disease with extensive heterogeneity in 
disease presentation between patients, which is likely 
due to an underlying molecular diversity. Here, we aimed 
at elucidating the genetic aetiology of SLE from the 
immunity pathway level to the single variant level, and 
stratify patients with SLE into distinguishable molecular 
subgroups, which could inform treatment choices in SLE.
Methods We undertook a pathway- centred approach, 
using sequencing of immunological pathway genes. 
Altogether 1832 candidate genes were analysed in 958 
Swedish patients with SLE and 1026 healthy individuals. 
Aggregate and single variant association testing was 
performed, and we generated pathway polygenic risk 
scores (PRS).
Results We identified two main independent pathways 
involved in SLE susceptibility: T lymphocyte differentiation 
and innate immunity, characterised by HLA and 
interferon, respectively. Pathway PRS defined pathways 
in individual patients, who on average were positive for 
seven pathways. We found that SLE organ damage was 
more pronounced in patients positive for the T or B cell 
receptor signalling pathways. Further, pathway PRS- 
based clustering allowed stratification of patients into 
four groups with different risk score profiles. Studying 
sets of genes with priors for involvement in SLE, we 
observed an aggregate common variant contribution to 
SLE at genes previously reported for monogenic SLE as 
well as at interferonopathy genes.
Conclusions Our results show that pathway risk scores 
have the potential to stratify patients with SLE beyond 
clinical manifestations into molecular subsets, which 
may have implications for clinical follow- up and therapy 
selection.
INTRODUCTION
Systemic lupus erythematosus (SLE) is character-
ised by the production of autoantibodies targeting 
nucleic acids and associated proteins, immune 
complex formation and inflammation in multiple 
organs. There is a wide spectrum of clinical mani-
festations in SLE and extensive heterogeneity in 
disease presentation between patients; in addition, 
the treatment response is often unpredictable.1 
The pathogenesis of SLE has partially been clari-
fied during the last years, and important features 
are increased expression of type I interferon (IFN) 
regulated genes, defects in the apoptotic process 
and activated autoreactive B cells.1 2 The reasons 
Key messages
What is already known about this subject?
 ► The clinical heterogeneity in systemic lupus 
erythematosus (SLE) is likely due to an 
underlying molecular diversity that could have 
implications for therapy.
 ► In recent years, gene expression, autoantibody 
profiles and cytokine levels have been used 
to identify groups of patients with SLE with 
distinct molecular disease mechanisms.
What does this study add?
 ► We have presented a novel strategy to 
genetically stratify SLE patients according to 
involved molecular pathways.
 ► Using genetic information to stratify patients 
would have the advantages of providing stable 
molecular markers for early classification.
How might this impact on clinical practice or 
future developments?
 ► Our results show that pathway risk scores have 
the potential to stratify SLE patients beyond 
clinical manifestations into molecular subsets, 
which may have implications for clinical follow- 
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behind these abnormalities are both environmental and genetic, 
and today around 100 SLE susceptibility loci have been iden-
tified.3 4 Monogenic forms of SLE exist, but for a majority of 
patients the environment and the cumulative number of suscep-
tibility alleles will influence the risk of developing the disease.4 5
To date, the contribution of rare genetic variants and the 
impact of regulatory variants have not been widely explored in 
SLE. DNA sequencing has the potential to discover novel SLE 
associated variants not captured by genotyping arrays. Due to 
the high cost, whole genome sequencing studies (WGS) in SLE 
have so far mainly focused on families or smaller samples, as 
have exome sequencing studies (WES).6–9 Today it is feasible 
to perform targeted sequencing in larger cohorts; however, the 
number of such studies focusing on SLE is still limited.10 Addi-
tionally, association analysis for rare variants discovered through 
sequencing is hampered by low statistical power. Aggregating 
variants on the gene level or by molecular pathway information 
is one approach to increase power and gain biological insight 
from rare variants.11
The clinical heterogeneity in SLE is likely due to an underlying 
molecular diversity that could have implications for therapy. 
In recent years this has started to be addressed, mainly using 
gene expression, autoantibody profiles and cytokines to iden-
tify groups of patients with SLE with distinct molecular disease 
mechanisms.12–14 Using genetic information to stratify patients 
would have the advantage of providing stable molecular markers 
for early classification.
Here, we performed targeted sequencing of regulatory and 
coding regions in a Swedish SLE case–control cohort. We aimed 
at elucidating the genetic aetiology of SLE from the immunity 
pathway level to the single variant level, and stratify patients 
with SLE into molecular subgroups. Altogether around 9% of 
all genes in the human genome were analysed based on their 
role in immune- mediated diseases. Gene regions were extended 
to include promoters and other potentially regulatory elements 
based on mammalian conservation.15
METHODS
For full details on methods see online supplemental methods.
Subjects and DNA samples
The Swedish SLE cohorts included patients recruited at five rheu-
matology clinics and the controls were healthy blood donors and 
population controls. The quality- controlled dataset comprised 
958 patients with SLE and 1026 control individuals. Patients 
with SLE fulfilled at least four of the classification criteria for 
SLE as defined by the American College of Rheumatology 
(ACR).16 17 Clinical characteristics of the patients are available in 
online supplemental tables S1A and B.
Targeted DNA sequencing analysis
Targeted DNA sequencing was performed in the Swedish SLE 
case–control cohorts. A SeqCap EZ Choice XL sequence capture 
panel was designed, libraries were prepared as described else-
where18 and sequenced on an Illumina HiSeq 2500. An overview 
of the variant discovery and quality control steps can be found 
in online supplemental figure S1. Study subjects falling outside 
of the European subpopulation of the Human Genome Diver-
sity Project (HGDP) reference set were excluded (online supple-
mental figure S7).19 The quality- controlled dataset contained 
287 354 single- nucleotide variants (SNVs) and covered 1832 of 
the targeted gene regions.
Genetic association analyses
Several variant sets were generated for aggregate association 
testing: (1) 1832 individual gene variant sets; (2) 35 pathway 
variant sets based on the Kyoto Encyclopaedia of Genes and 
Genomes (KEGG)20 ; (3) five literature review gene sets: the 
type I interferon pathway,21 interferonopathy genes,22 23 SLE 
Genome- Wide Association Study (GWAS) genes,3 4 the comple-
ment subset of KEGG hsa04610 and genes causing monogenic 
SLE or lupus- like disease.24 Aggregate association testing was 
performed using Sequence Kernel Association Optimal Test 
(SKAT- O) or GenePy.25 26 Single variant association analyses were 
performed in PLINK. SLE case- only variants were identified by 
removing all SNVs present in our Swedish control dataset, the 
SweGen project or the Genome Aggregation Database European 
non- Finnish controls.27 28
Risk scores and cluster analysis
Cumulative pathway SLE polygenic risk scores (pathway PRSs) 
were assigned to each individual based on SNVs associated with 
SLE at nominal significance. For each independent SNV the 
natural logarithm of the OR for SLE susceptibility was multi-
plied by the number of minor alleles in each individual. The sum 
of all products of all genes in each of the 35 KEGG pathways for 
each patient was defined as the individual pathway PRS. Hier-
archical cluster analysis of pathway PRSs was used to identify 
groups of patients with SLE.
Replication study and meta-analysis
Replication genotyping in individuals from Norway and Denmark 
was performed using the MassARRAY system. The Swedish SLE 
case–control study was expanded to include an additional 1000 
control individuals.27 The Scandinavian meta- analysis included 
1794 patients with SLE and 3241 control individuals.
RESULTS
We performed a DNA sequencing study in SLE to study immu-
nity pathways, an overview of analyses can be found in online 
supplemental figure S2.
T lymphocyte differentiation and innate immunity pathways 
are associated with SLE
The sequencing data analysis focused on 1832 genes with rele-
vance for immune- mediated diseases. These genes mainly belong 
to 35 molecular signalling pathways as defined by the KEGG 
database (online supplemental table S2).20 Using an aggregate 
test for all variants in the genes belonging to each pathway, we 
found that 21 of the tested pathways were associated with SLE 
(false discovery rate (FDR) <0.05, table 1 and online supple-
mental table S3). The most significantly associated pathways 
included T helper cell differentiation pathways, with Th1 and 
Th2 cell differentiation as the top result (FDRTh1-2=2.2×10
-9; 
FDRTh17=1.5×10
-8), followed by antigen processing and presen-
tation (FDR=3.1×10-9).
We next explored a sequential elimination strategy to iden-
tify independent pathway associations. First, removing all Th1 
and Th2 pathway genes in the pathway aggregate association 
test resulted in the antigen processing and presentation pathway 
as the top result (FDR=4.8×10-6). Second, antigen processing 
and presentation as well as Th1 and Th2 pathway genes were 
removed, which resulted in Complement and coagulation 
cascades as the top result (FDR=0.0091). Third, also genes in this 
pathway were removed, and the janus kinase- signal transducers 
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top result (FDR=0.014). Lastly, when removing genes in all 
these four pathways no significant pathways remained. Thus, 
our data point to two main routes with genetic evidence of asso-
ciation to SLE: T cell differentiation and innate immunity.
To identify the genes that underlie the association signals in 
the T- cell differentiation, antigen processing and presentation, 
Complement and coagulation and JAK- STAT pathways, gene- 
based association testing was performed (figure 1). The top 
association for the JAK- STAT pathway originated from the IFN 
kappa (IFNK) gene region. SLE- associated genes in the T cell 
differentiation and antigen processing and presentation path-
ways were dominated by genes in the HLA region, and for the 
complement and coagulation cascade pathway, complement 
genes located in the HLA region were highly significantly asso-
ciated with SLE.
Pathway PRS define subsets of patients with SLE
Having identified pathways with genetic association with SLE, 
we hypothesised that different patients with SLE could have 
distinct pathways affected. We constructed pathway PRS for 
each individual and each of the pathways, by combining the 
burden of common SLE associated alleles from our sequencing 
data. Individuals with a pathway PRS higher than that observed 
for the 97.5th percentile of control individuals were classified 
as positive for that pathway (online supplemental figure S3). 
The largest proportion of positive SLE patients was observed 
for the Cytokine- cytokine receptor interaction pathway (41%, 
figure 2A, and online supplemental table S4). For the Th1 and 
Th2 cell differentiation, antigen processing and presentation, 
Complement and coagulation cascades and JAK- STAT signalling 
pathways 18%, 16%, 21% and 29% of patients with SLE were 
positive, respectively. On average each SLE patient tested positive 
for the pathway PRS for seven pathways (figure 2B). As we had 
previously observed that a high SLE genetic risk score was asso-
ciated with organ damage in SLE, we investigated whether this 
could be observed for specific pathways.5 We found that the SLE 
International Collaborating Clinics Damage Index was signifi-
cantly higher in the SLE patients positive for the T cell or B cell 
receptor signalling pathways (figure 3A,B). No other pathways 
were associated with clinical manifestations of SLE or survival.
We then performed a hierarchical cluster analysis on the 
pathway PRSs in SLE, to identify groups of patients with similar 
molecular aetiology. Four clusters of patients were identified 
(figure 4). The pathway with the most significant difference in 
PRS between clusters was the antigen processing and presen-
tation pathway, followed by Th17 cell differentiation (online 
supplemental figure S4). Next, we investigated whether the 
molecular stratification of patients with SLE also mirrored differ-
ences in clinical presentation between groups. We found that the 
presence of autoantibodies against Sjögren’s syndrome- related 
antigens SSA and/or SSB was more common among patients in 
clusters 3 and 4 (figure 3C). We did not observe any significant 
difference in other clinical features, including survival, between 
the four patient clusters.
Common variants contribute risk at monogenic risk loci in SLE
We then focused our analysis on gene- sets with prior evidence 
for involvement in SLE, but which were not defined in KEGG, 
to investigate the impact of both rare and common variants for 
these groups of genes. We found that interferon system, inter-
feronopathy, SLE GWAS, complement system and monogenic 
SLE and lupus- like disease genes in aggregate were associated 
with SLE when analysing variants of all minor allele frequen-
cies (MAF) (table 2 and online supplemental table S5). Only the 
Table 1 SLE case–control pathway based aggregate association analysis
Pathway Genes in pathway Genes in test SNVs in test P value* FDR†
Th1 and Th2 cell differentiation (hsa04658) 92 78 14 362 6.3E-11 2.2E-09
Antigen processing and presentation (hsa04612) 77 40 8017 1.8E-10 3.1E-09
Hematopoietic cell lineage (hsa04640) 97 71 13 013 3.8E-10 4.5E-09
Th17 cell differentiation (hsa04659) 107 96 19 347 1.7E-09 1.5E-08
Intestinal immune network for IgA production (hsa04672) 49 39 7909 3.4E-08 2.4E-07
Natural killer cell- mediated cytotoxicity (hsa04650) 131 100 15 821 4.7E-06 2.8E-05
TNF signalling pathway (hsa04668) 112 88 12 639 1.9E-05 9.4E-05
JAK- STAT signalling pathway (hsa04630) 162 133 18 003 7.4E-05 0.00032
RIG- I- like receptor signalling pathway (hsa04622) 70 63 8459 0.00021 0.00080
NOD- like receptor signalling pathway (hsa04621) 178 109 15 729 0.00031 0.0011
Complement and coagulation cascades (hsa04610) 79 50 7112 0.00041 0.0013
Toll- like receptor signalling pathway (hsa04620) 104 96 12 178 0.00080 0.0022
Cytokine- cytokine receptor interaction (hsa04060) 294 221 26 771 0.00083 0.0022
C- type lectin receptor signalling pathway (hsa04625) 104 75 12 986 0.0020 0.0050
IL-17 signalling pathway (hsa04657) 93 68 9358 0.0043 0.0100
Fc epsilon RI signalling pathway (hsa04664) 68 51 8514 0.0052 0.011
Viral protein interaction with cytokine and receptor (hsa04061) 100 75 8435 0.0062 0.013
NF- kappa B signalling pathway (hsa04064) 102 88 14 349 0.0078 0.015
Osteoclast differentiation (hsa04380) 128 101 18 602 0.013 0.023
T cell receptor signalling pathway (hsa04660) 103 85 14 268 0.014 0.025
Cytosolic DNA- sensing pathway (hsa04623) 63 40 4993 0.015 0.025
Pathways with FDR <0.05 in the association analysis including all genes are presented.
*SKAT- O SLE case- control association p value.
†SKAT- O SLE case–control association FDR.
FDR, false discovery rate; IL-17, interleukin 17; NF, nuclear factor; NOD, nucleotide- binding oligomerisation domain; RIG, retinoic acid- inducible gene; SKAT- O, sequence kernel 
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monogenic SLE and lupus- like disease gene- set was significantly 
associated with SLE when separately analysing the rarer variant 
(MAF <0.01) contribution (table 2). There was a clear common 
variant (MAF >0.05) contribution to associations for the inter-
feronopathy, SLE GWAS, complement system and monogenic 
SLE and lupus- like disease gene- sets (table 2).
Potentially novel SLE risk loci
Next, we asked whether we could detect novel SLE risk loci, 
regardless of pathway or gene- set membership. Two potentially 
novel gene regions passed a Bonferroni corrected threshold in 
the gene- based SLE case–control association analyses: PABPC4 
(p=4.3×10-8) and IFNK (p=1.2×10-5, online supplemental 
figure 5A, tables S6 and S7). In single variant association analyses, 
we observed SNV associations at three potentially novel SLE risk 
loci, CAPN13, MOB3B/IFNK and HAL, at a suggestive signifi-
cance threshold (p<1×10-4, online supplemental figure 5B–E, 
table S8). As the association signals at CAPN13, MOB3B/IFNK 
and HAL had not been reported in SLE GWAS in other ances-
tries, we attempted to replicate these findings in additional 
Scandinavian SLE cases and controls (online supplemental table 
S1A). However, we did not find additional support for a role of 
SNVs at these novel loci in SLE (online supplemental table S9).
Patients with SLE carry unique coding variants
We next investigated whether there was an increased rare coding 
mutational burden for patients with SLE at the 1832 genes. 
We observed that all individuals carried rare non- synonymous 
Figure 1 Results of SLE case–control gene- based association analyses. P values for association plotted against chromosomal location, where 
each point represents a gene region. The line indicates a false discovery rate of 5%. The y- axis has been cut at p=1×10-15. Genes belonging to 
the T- cell differentiation (Th1 and Th2), antigen processing and presentation, complement and coagulation or JAK- STAT signalling pathways are 
highlighted, and their most significant genes or gene regions are indicated by name. IFNK, interferon kappa; IL21, interleukin 21; SLE, systemic lupus 
erythematosus.
Figure 2 Pathway SLE polygenic risk scores. (A) Illustrates pathway Polygenic Risk Scores (PRS) for the Cytokine–cytokine receptor interaction 
pathway. P values represent differences in PRS between patients with SLE (SLE) and healthy control individuals (HC). The dashed line indicates the 
PRS 97.5 percentile in control individuals. (B) The number of pathways each individual patient with SLE tested positive for using the pathway PRS. On 
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variants, with an average number of around 32 variants per indi-
vidual for both patients with SLE and control individuals (online 
supplemental figure S6). None of the patients with SLE were 
homozygous carriers of rare non- synonymous alleles in genes 
for monogenic SLE and lupus- like diseases (online supplemental 
table S10). Next, we hypothesised that protein coding variants 
observed exclusively in patients with SLE could be causal candi-
dates. A total of 1475 case- only nonsynonymous variants were 
identified in the 958 patients with SLE (online supplemental 
table S11). These were variants that were observed in at least 
one patient with SLE, but not in control individuals of similar 
ancestry.27 28 The most frequent of these SNVs was found in the 
MUC5B gene which encodes mucin 5B, the major gel- forming 
mucin in mucus (table 3). Five patients with SLE carried the 
same deleterious MUC5B missense mutation (rs773068050, 
p.Thr2724Pro). MUC5B gene variants have previously been asso-
ciated with interstitial lung disease (ILD), a condition affecting 
around 3% of Swedish patients with SLE.29–31 However, there 
was no evidence of ILD in these five patients, but two of them 
had suffered from pleuritis (online supplemental table S12). In 
conclusion, we did not find evidence for SLE patients carrying a 
generally increased burden of rare coding variants at these genes. 
However, our analysis identified a number of coding variants 
observed exclusively in patients with SLE. This catalogue of vari-
ants could serve as a resource for future studies investigating the 
role of case- only SNVs in SLE.
Figure 3 Pathway SLE polygenic risk scores grouping and clustering. (A, B) The Systemic Lupus Erythematosus International Collaborating Clinics 
(SLICC) damage index for patients with SLE positive and negative for the T cell receptor and B cell receptor signalling pathways. P values represent 
differences in Damage Index between pathway positive and negative patients, uncorrected p values are presented (Bonferroni corrected threshold 
p=0.00143). (C) Prevalence of Sjögren’s syndrome (SSA and/or SSB) autoantibodies in SLE patients in the four clusters. P value represent difference in 
SSA/SSB autoantibody status between clusters of SLE patients, uncorrected p value is presented (Bonferroni corrected threshold p=0.002).
Figure 4 Clustering of patients with SLE based on pathway Polygenic Risk Scores (PRS). Heat map with pathways on the x- axis (KEGG IDs) and 
individuals on the y- axis based on normalised PRS. Hierarchical cluster analysis was performed based on the PRS per pathway for each individual. The 
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DISCUSSION
We here suggest a novel pathway- based approach to stratify 
patients with SLE beyond clinical manifestations. Further, we 
characterise genetic pathway associations and investigate rare 
variant contributions to the pathogenesis of SLE, all using 
targeted sequencing of immunity genes.
Using case–control association testing for immunological 
pathways, we identified two main axes of SLE association: T 
cell differentiation and innate immunity pathways. T cells have a 
fundamental role in loss of tolerance, autoimmunity and inflam-
matory reactions. In SLE, a number of different T cell disturbances 
have been described, which can contribute to the generation of 
autoreactive T cells, aberrant cytokine production and impaired 
T regulatory cell function.32 Besides the direct involvement of 
pathways connected to Th1 and Th2 cells, we noticed associa-
tion signals from two pathways related to interleukin 17 (IL-17). 
A proportion of patients with SLE display raised serum levels 
of IL-17, elevated numbers of circulating IL-17- producing T 
cells and increased IL-17 production by lymphocytes, suggesting 
dysregulation of T regulatory cells.33 Our findings strengthen the 
recent suggestions that IL-17 inhibition could be a therapeutic 
option in a subset of patients with SLE.34 Conversely, low- dose 
IL-2 treatment in SLE to stimulate T regulatory cells has recently 
shown promising results.35
We observed that the T cell differentiation pathway associ-
ations were influenced by genetic associations to HLA, which 
is not surprising given the essential role of HLA in the immune 
response. This was further demonstrated by the antigen 
processing and presentation pathway association dominated by 
HLA genes. Complement pathway associations are also possibly 
confounded by the HLA SLE association, since early comple-
ment component genes are located in the HLA class III locus on 
chromosome 6.36 The JAK- STAT pathway was associated with 
SLE, it is the main route to initiate gene expression and protein 
synthesis for over 50 cytokines, many of which are involved in 
the SLE disease process.37 38 Variants of a number of genes in the 
JAK- STAT pathway have been associated with an increased risk 
for SLE, for instance STAT4- STAT1 and TYK2.3 4
Our study highlights the importance of the interferon system 
in SLE. Previous studies have shown genetic associations at a 
number of genes in the IFN signalling pathway in SLE.2 3 Here, 
we show that, in aggregate, genetic variation at interferonopathy 
Table 2 Gene- set analyses of SLE- associated genes and involved pathways
Set name Genes tested No of SNVs all/common/rare FDRALL FDRCOMMON FDRRARE
Interferon (ref 21) 33 4204/849/2866 0.0018 0.66 0.65
Interferonopathy (ref 22,23) 11 2034/463/1271 0.0028 4.1E-07 0.24
SLE GWAS (ref 3,4) 88 18790/5326/11465 1.5E-12 2.0E-15 0.18
Complement* 32 4712/1094/3086 0.00071 2.8E-07 0.20
Monogenic SLE (ref 24) 24 3745/930/2371 2.9E-07 2.9E-11 0.020
All: including all MAFs; Common: MAF >0.05; Rare: MAF <0.01.
*The complement part of KEGG pathway hsa04610.
FDR, false discovery rate; GWAS, genome- wide association study; KEGG, kyoto encyclopedia of genes and genomes; MAF, minor allele frequency; SLE, systemic lupus 
erythematosus; SNV, single- nucleotide variant.
Table 3 SLE case- only recurrent non- synonymous SNVs
CHR BP SNV Ref allele Alt allele Count SLE Gene Consequence
Amino acid 
change SIFT
11 1 266 280 rs773068050 A C 5 MUC5B Missense variant p.Thr2727Pro Deleterious(0.05)
1 186 363 103 rs1292231132 C A 4 C1orf27 Missense variant p.Gln246Lys Tolerated(0.21)
1 151 342 270 rs772030489 G T 2 SELENBP1 Missense variant p.Pro36Thr Deleterious low 
confidence(0.01)
2 27 455 971 rs776014297 T A 2 CAD Missense variant p.Met922Lys Deleterious(0.04)
2 179 698 928 rs892049188 G A 2 CCDC141 Missense variant p.Ser1522Phe Tolerated(0.08)
9 16 431 447 chr9:16 431 447 G A 2 BNC2 Missense variant p.His307Tyr –
9 21 166 175 rs779242420 T C 2 IFNA21 Missense variant p.Tyr146Cys Deleterious(0.01)
10 75 583 821 chr10:75 583 821 G T 2 CAMK2G Missense variant p.His370Asn Deleterious low 
confidence(0.03)
12 6 458 353 rs775543049 G A 2 SCNN1A Stop gained p.Arg551* –
12 48 482 728 rs750735162 T C 2 SENP1 Missense variant p.Thr155Ala Deleterious low 
confidence(0)
12 56 350 882 rs1425141530 G T 2 PMEL Missense variant p.Pro402His Deleterious(0.02)
12 129 190 793 rs1386045604 C G 2 TMEM132C Missense variant p.Pro1094Ala Tolerated(0.21)
14 23 057 866 chr14:23 057 866 A T 2 DAD1 Missense variant p.Ser66Arg Deleterious(0.04)
15 91 030 272 rs181919733 G A 2 IQGAP1 Missense variant p.Val1371Met Tolerated(0.07)
17 41 143 320 rs1456586259 G A 2 RUNDC1 Missense variant p.Val477Ile Tolerated(0.12)
19 4 891 395 rs139019426 T C 2 ARRDC5 Missense variant p.Gln231Arg Tolerated(0.86)
19 18 273 781 rs777121279 G A 2 PIK3R2 Missense variant p.Gly372Ser Deleterious(0)
19 55 240 959 rs764066889 G A 2 KIR3DL3 Missense variant, 
splice region variant
p.Gly219Asp Deleterious(0.02)
SIFT (Sorting Intolerant From Tolerant) prediction whether the amino acid substitution affects protein function.


















is: first published as 10.1136/annrheum





115Sandling JK, et al. Ann Rheum Dis 2021;80:109–117. doi:10.1136/annrheumdis-2020-218636
Systemic lupus erythematosus
genes also contribute to risk for SLE. In addition to interferonop-
athy genes, we also observed an aggregate genetic association for 
monogenic SLE and lupus- like disease genes with both a rare and 
a common variant contribution. This supports the hypothesis of a 
shared genetic basis and consequently disease mechanisms between 
monogenic and complex forms of disease, where also common 
non- coding variants can affect the regulation of Mendelian disease 
genes resulting in clinically similar traits.39
We have previously demonstrated that an SLE genetic risk score 
was associated with disease severity in SLE.5 We here generated a 
pathway- centred SLE PRS and found that there was a large variation 
in the number of affected pathways among the patients, which under-
scores the heterogeneity of SLE. We observed higher SLE damage 
indexes in patients with SLE positive for the B or T cell receptor 
signalling pathways, thus, pathways in the adaptive immune system 
seem important for the long- term severity of the disease. This is in 
accordance with previous findings that SLE disease activity correlates 
with abnormal B lymphocyte activity and T cell abnormalities, as 
well as the connection between disease activity and accumulation of 
organ damage.40 41
We attempted to cluster patients into subsets with shared 
genetic pathway profiles, which suggested four subgroups of 
patients with SLE. Beside the SSA/SSB antibody profile, these 
clusters were not connected to clinical disease manifestations 
such as nephritis or survival. This observation may indicate that 
the PRS reflects part of the central autoimmune process, which 
is not translated into specific organ manifestations. Whether the 
PRS in individual patients with SLE, or the different clusters, 
contribute to treatment response is an interesting possibility, but 
could not be assessed in this study. This is one limitation of our 
study, together with the fact that our conclusions apply specifi-
cally to this set of candidate genes.
WGS or WES studies will be required to fully elucidate the role of 
rare variants and pathways in SLE. As previously shown by us and 
others, WGS and WES in selected patients can provide information 
on ultrarare and de novo SNVs in SLE.6 7 42 However, larger sample 
sizes than those reported to date will be required to paint a complete 
picture of the genetic aetiology of SLE. We did not find support 
in additional Scandinavian cohorts for a role in SLE for the novel 
loci identified in the Swedish cohorts. Possible explanations include 
overestimated effect sizes in the discovery cohort, differences in 
genetic background within Scandinavia, or differences in clinical 
manifestations or characterisation of patients. Lastly, our study iden-
tified a large number of case- only coding variants. Variants uniquely 
identified in patients could be causal candidates in SLE, but their 
statistical significance is difficult to evaluate.
In summary, we have suggested a novel strategy to genetically 
stratify patients with SLE according to involved molecular pathways. 
T cell pathways displayed the strongest association, which highlights 
the importance of the adaptive immune system in the disease. The 
strong connection to the JAK- STAT pathway, including the IFN 
system, is perhaps not surprising given the promising clinical trials 
of JAK and type I interferon receptor inhibition as treatments for 
SLE.38 43 44 However, not all patients in these studies respond to 
treatment, and dissecting affected molecular pathways in responders 
and non- responders could increase the understanding of treatment 
outcome. This approach has not been tested clinically, but the future 
of precision medicine for SLE lies in identifying robust methods to 
perform molecular stratification of patients.
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